---
document_datetime: 2026-02-11 12:14:47
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lumark-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lumark-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.7158211
conversion_datetime: 2026-02-13 18:43:47.731954
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                   | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                       |
|----------------------|-------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10391 /201912  | Periodic Safety Update EU Single assessment - lutetium (177Lu) chloride | 23/07/2020                                  | 17/09/2020                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10391/201912.                                                                                    |
| R/0014               | Renewal of the marketing authorisation. Medicinal                       | 27/02/2020                                  | 23/04/2020                                  | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lumark in the approved indication remains favourable and therefore recommended the renewal of the marketing |

EMA/511051/2020 Lumark Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                           |            |               |             | authorisation with unlimited validity.                                                                                                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0015             | B.II.e.1.z - Change in immediate packaging of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                      | 28/11/2019 | n/a           |             |                                                                                                                                                       |
| PSUSA/10391 /201812 | Periodic Safety Update EU Single assessment - lutetium (177Lu) chloride                                                                                                                                                                                                                                                                                                                                                   | 25/07/2019 | 19/09/2019    | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10391/201812. authorised |
| IB/0012             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                             | 03/04/2019 | n/a           | longer      |                                                                                                                                                       |
| PSUSA/10391 /201806 | Periodic Safety Update EU Single assessment - lutetium (177Lu) chloride                                                                                                                                                                                                                                                                                                                                                   | 31/01/2019 | 02/04/2019    | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10391/201806.            |
| N/0010              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                          | 02/10/2018 | 02/04/2019 no | Labelling   |                                                                                                                                                       |
| PSUSA/10391 /201712 | Periodic Safety Update EU Single assessment - lutetium (177Lu) chloride product                                                                                                                                                                                                                                                                                                                                           | 26/07/2018 | 20/09/2018    | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10391/201712.            |
| IB/0009/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation Medicinal | 21/08/2018 | n/a           |             |                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| PSUSA/10391 /201706   | Periodic Safety Update EU Single assessment - lutetium (177Lu) chloride                                                                       | 25/01/2018   | 04/04/2018    |                            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10391/201706.   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0007               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 09/02/2018   | n/a           |                            | authorised                                                                                                                                   |
| PSUSA/10391 /201612   | Periodic Safety Update EU Single assessment - lutetium (177Lu) chloride                                                                       | 20/07/2017   | 18/09/2017    | SmPC and PL longer         | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10391/201612.   |
| PSUSA/10391 /201606   | Periodic Safety Update EU Single assessment - lutetium (177Lu) chloride                                                                       | 12/01/2017   | n/a           |                            | PRAC Recommendation - maintenance                                                                                                            |
| IAIN/0004             | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release product            | 11/01/2017   | 18/09/2017 no | Annex II, Labelling and PL |                                                                                                                                              |
| T/0002                | Transfer of Marketing Authorisation                                                                                                           | 03/08/2016   | 22/08/2016    | SmPC, Labelling and PL     |                                                                                                                                              |
| PSUSA/10391 /201512   | Periodic Safety Update EU Single assessment - lutetium (177Lu) chloride Medicinal                                                             | 07/07/2016   | n/a           |                            | PRAC Recommendation - maintenance                                                                                                            |